Effect of epoprostenol (prostacyclin, PGI₂) on cerebral blood flow in man

MM BROWN,* HILARY PICKLES†

From the Institute of Neurology, Queen Square,* and the Department of Clinical Pharmacology, St. Bartholomews Hospital,† London, UK

SUMMARY Cerebral blood flow has been measured using the non-invasive Xenon¹³³ clearance technique in eight normal subjects during an infusion of epoprostenol (prostacyclin, PGI₂) at a dose of 5 ng/kg/min. The results were compared with a control infusion of saline given in a balanced order. PGI₂ was found to result in a reduction in cerebral blood flow of about 8%. PGI₁ also caused a small drop in diastolic blood pressure and it is proposed that the fall in cerebral blood flow may have been the result of disturbed autoregulation. The findings suggest that the therapeutic use of PGI₁ in patients with cerebral artery spasm would not be accompanied by undesirable intracerebral steal.

It was proposed by Pickard and Mackenzie in 1973¹ that a vasodilatory endogenous prostaglandin with a rapid turnover was responsible for maintaining the normal level of cerebral blood flow. Epoprostenol (prostacyclin, PGI₂) is the most suitable candidate for such a role. A product of arachidonic acid metabolism, it is formed in vascular endothelium,² including that of cerebral vessels.³ ⁴ It is a potent dilator of cerebral blood vessels in vitro⁵ ⁶ and has been found to increase cerebral blood flow (CBF) in baboons when infused into the carotid artery.⁷ It has been suggested that PGI₁ might have a therapeutic role in conditions associated with cerebral arterial spasm, such as subarachnoid haemorrhage.⁸ ⁹ In addition to its vasodilatory properties, PGI₂ is a potent inhibitor of platelet aggregation, and for this reason might also find application in a wider range of cerebrovascular conditions. We have therefore investigated the effects of exogenous PGI₁ on CBF in normal human subjects. PGI₂ is rapidly broken down in the circulation and therefore has to be given by infusion.

Methods

Eight clinically normal subjects, four male and four female, with a mean age of 22 years (range 19–33) were studied. The study was approved by the Ethics Committee of the National Hospital, Queen Square and the subjects gave their informed consent. Each subject had two estimations of CBF separated by about 1 h. During one CBF measurement, the subject received a control infusion of 0-9% saline into an indwelling catheter in a forearm vein, and during the other measurement an infusion of PGI₁ at a dose of 5 ng/kg/min. PGI₁, synthesised by Upjohn and formulated by the Wellcome Foundation, was diluted in glycine buffer at pH 10.5 and given by constant infusion pump at a rate of 0-2 ml/min. This infusion was given for 10 min prior to the start of the CBF estimation, by which time other dynamic effects of PGI₁ were apparent, and continued throughout the flow measurement. The order of treatments was balanced so that four subjects received PGI₁ and four subjects saline as the first infusion. The infusions were not given blind, as we have found that characteristic facial flushing with PGI₁ makes it obvious which treatment has been given.

CBF was measured by the non-invasive intravenous Xenon¹³³ (Xe¹³³) clearance technique, details of which are given elsewhere.⁹ In brief, a bolus of approximately 7 mCi of Xe¹³³, dissolved in saline, was injected into a forearm vein and the clearance of the isotope from the cerebral hemispheres monitored for 15 minutes with six external 25 mm diameter scintillation detectors. Expired concentrations of Xe¹³³ were monitored with a seventh detector and the end-tidal levels used to estimate recirculating arterial Xe¹³³ concentrations. Regional CBF
was calculated from a bicompartiment analysis of 11.5 minutes of the clearance data and also from an initial slope analysis of the first 1 minute of the clearance curves. These analyses resulted in figures for volumetric blood flow through the fast clearing tissues of the brain which are mainly grey matter (F fast), and a figure for flow to the whole brain (F initial). The CBF values presented for each subject are the means of the six regional measurements.

Blood pressure was recorded from the left arm with a standard mercury sphygmomanometer and the pulse rate measured over 30 seconds from the radial pulse on three occasions during the CBF measurement. Arterial partial pressure of carbon dioxide (pCO₂) was estimated by monitoring expiratory CO₂ concentration with a Datex CD 300 infra red analyser. The pCO₂ levels were calculated from the mean end tidal concentration over the first 5 minutes of the blood flow measurement. Venous red cell haematocrit (PCV) was measured in a Hawksley microhaematocrit centrifuge.

**Results**

The results are presented in this table. Compared with the saline infusion, PGI₂ resulted in small but significant reduction in mean CBF of 7.3 ml/100g/min (F fast) and 5.1 ml/100g/min (F initial). There was no significant change in PCV or arterial pCO₂ that might have influenced the results. The pattern of end tidal Xe concentration was not altered by the PGI₂ infusion and it is therefore unlikely that there were alterations in the ratio of arterial to expired Xe concentrations that might have influenced the accuracy of the correction for arterial recirculation.

During the infusion of PGI₂, all subjects developed a marked facial flush, a moderate tachycardia (mean rise in pulse rate = 12.3, p < 0.01) and a small fall in diastolic blood pressure (mean fall = 9.4 mmHg, p = < 0.01). Systolic blood pressure rose in five out of the eight subjects but the mean rise of 3.4 mmHg was not statistically significant. Four subjects complained of headache, and three others a slight heaviness in the head, 3 had palmar flushing and 1 suffered from nausea and restlessness.

**Discussion**

This study has demonstrated that, contrary to expectations, epoprostenol (prostacyclin, PG₁₂) given intravenously results in a slight fall in mean CBF in normal subjects. Since completing our work another group has briefly reported similar findings in man using a dose of 4 ng/kg/min. The dose of 5 ng/kg/min used in the current study is the highest intravenous infusion rate than can be readily tolerated by conscious humans and even this dose is greatly in excess of normal circulating endogenous PGI₂. The findings contrast with the effects of giving PGI₁ in relatively enormous doses (5000 ng/kg/min) directly into the carotid arteries of anaesthetised baboons, when an increase in CBF has been reported. We note that the lowest dose at which dilator effects of PGI₂ has been seen on cerebral vessels in vitro exceeds both the normal circulating level and that we might expect to attain during an infusion. The blood brain barrier might reduce the effective dose delivered by an intravenous infusion even further.

The effects of PGI₂ on blood pressure, pulse and the symptoms experienced by the subjects in the current study were similar to those found in previous work and are discussed in more detail elsewhere. It seems likely that the headache frequently reported during PGI₂ infusion is the result of vasodilatation occurring in the external carotid circulation (as demonstrated by the facial flush), although the current results do not exclude the possibility that the headache results from changes in the calibre of larger intracranial vessels that are not reflected by alterations in cerebral perfusion.

One possible explanation for the fall in CBF recorded in man lies in the effects of PGI₁ elsewhere in the body. The large drop in peripheral resistance during PGI₁ infusion is only partly compensated by the rise in cardiac output and a fall in diastolic pressure is usually recorded. PGI₁ has a differing effect on the various vascular beds, and it is probable

<p>| Table 1 Effect of epoprostenol (prostacyclin, PG₁₂) infusion on cerebral blood flow (F fast &amp; F initial) in 8 normal subjects |
|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|</p>
<table>
<thead>
<tr>
<th>Subject</th>
<th>Arterial BP systolic/diastolic mmHg</th>
<th>Arterial pCO₂ kPa</th>
<th>Arterial pCO₂ CO₂ kPa</th>
<th>F fast ml/100g/min Saline PGI₁</th>
<th>PGI₂</th>
<th>F initial ml/100g/min Saline PGI₁</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>115/70</td>
<td>117/65</td>
<td>5-4</td>
<td>5-3</td>
<td>100-5</td>
<td>92.3</td>
</tr>
<tr>
<td>2</td>
<td>130/88</td>
<td>125/82</td>
<td>5-0</td>
<td>5-1</td>
<td>82.5</td>
<td>72.6</td>
</tr>
<tr>
<td>3</td>
<td>132/87</td>
<td>152/85</td>
<td>4-6</td>
<td>4-7</td>
<td>74.5</td>
<td>74.9</td>
</tr>
<tr>
<td>4</td>
<td>138/83</td>
<td>140/80</td>
<td>5-9</td>
<td>5-8</td>
<td>116-0</td>
<td>102-9</td>
</tr>
<tr>
<td>5</td>
<td>136/82</td>
<td>144/68</td>
<td>5-3</td>
<td>4-7</td>
<td>74.1</td>
<td>59-5</td>
</tr>
<tr>
<td>6</td>
<td>110/72</td>
<td>106/58</td>
<td>5-3</td>
<td>5-4</td>
<td>87.5</td>
<td>95-6</td>
</tr>
<tr>
<td>7</td>
<td>110/67</td>
<td>115/57</td>
<td>5-7</td>
<td>5-6</td>
<td>107-1</td>
<td>91-2</td>
</tr>
<tr>
<td>8</td>
<td>128/85</td>
<td>127/64</td>
<td>6-1</td>
<td>5-6</td>
<td>100-6</td>
<td>95-4</td>
</tr>
<tr>
<td>Mean</td>
<td>125-79</td>
<td>128±70†</td>
<td>5-4</td>
<td>5-34</td>
<td>92-9</td>
<td>85-6*</td>
</tr>
</tbody>
</table>

Results during PGI₁ compared with saline using paired t tests: * p = < 0.05 † p = < 0.01 ‡ = NS.
that the increased cardiac output is directed mostly into vasodilated splanchnic and liver blood vessels rather than into muscle, renal or cerebral vessels. Clearly PGI₂ does not have a marked vasodilator effect on the human cerebrovascular bed at the dose we used and could have a slight vasoconstrictor effect. Alternatively, the fall in CBF recorded may have been the result of the excessive shunting of blood into organs of reduced vascular resistance and the small drop in perfusion pressure. However, CBF is normally maintained in the face of much larger changes in perfusion pressure by the process of autoregulation and the current results suggest that this autoregulation may have been disturbed by the presence of exogenous PGI₂.

It has been suggested that PGI₂ could be a useful therapeutic agent in cerebrovascular disease particularly subarachnoid haemorrhage because of its ability to overcome arterial spasm in vitro. The current results suggest that if used to treat cerebral artery spasm, PGI₂ would not result in vasodilation in normal areas of the brain and would therefore be unlikely to cause undesirable intracerebral diversion (intracerebral steal) of blood from ischaemic to normal areas. At the dose used in the present study, an effect on platelet aggregation would be expected, and thus PGI₂ may be able to prevent constrictor agents being released from platelets at sites of endothelial disruption and thus reduce cerebral artery spasm through this separate mechanism.

Failure to demonstrate an increase in CBF with PGI₂ does not necessarily exclude a role for PGI₂ in the normal regulation of CBF. Rapid resetting of the normal balance between endogenous dilator and constrictor influences in our subjects may have prevented a dilator effect of exogenous PGI₂. Pretreatment with salicylate or indomethacin, which is thought to inhibit the synthesis of endogenous prostaglandins such as PGI₂, causes an impaired dilatory response to hypercapnia and permits moderate doses of PGI₂ to increase cerebral blood flow after cerebral ischaemia in dogs. Acute pretreatment with indomethacin or salicylate may therefore provide conditions in man under which PGI₂ infusions will increase rather than decrease CBF and we are currently investigating this possibility.

We are very grateful to Professor John Marshall for his help and encouragement. This work was carried out while MMB was Research Fellow in Cerebral Blood Flow at The Institute of Neurology. HP was supported by the MRC. We thank the Wellcome Research Laboratories and Dr John O’Grady for providing the PGI₂ buffer and a financial contribution. Sister Sheila Redmond gave invaluable assistance and Mr E Zilkha kindly maintained the CBF and computing equipment.

References
2 Herman AG, Moncada S, Vane JR. Formation of prostacyclin (PGI₂) by different layers of the arterial wall. Arch Int Pharmacodyn Ther 1977;227:162–3.
17 Eklund B, Joretq T, Kajser L. Dissimilar effects of...


